MSDS 414-500
MSDS 415-500
MSDS 415A-500
MSDS 415F-500
MSDS 415-GS
MSDS 415K-500
Description
Use with:
Human Synoviocyte Media, for sterile, in vitro culture of fibroblast-like synovial cells that line the joint.
Details
CAI media are tested for sterility in order to confirm no bacteria, yeast or fungi contaminate the solutions. The products undergo further quality control for correct pH, osmolality and lack of endotoxins. A panel of different bioassays affirm the media sustain a proper environment for expected cell-type-specific culture, growth, plating, karyotype, physiology, morphology, viability, population doublings, surface markers, cryopreservation, differentiation and/or induction.
Laboratory research use only (RUO). Not for human, clinical, diagnostic or veterinary use.
Products
| Product | Size | CAT.# | Price | Quantity |
|---|---|---|---|---|
| HFLS Basal Medium: Basal medium (contains no growth supplement). Add GS before use. | Size: 500 ml | CAT.#: 414-500 | Price: $70.00 | |
| HFLS Growth Medium: All-in-one ready-to-use | Size: 500 ml | CAT.#: 415-500 | Price: $117.00 | |
| HFLS Growth Medium wo Antibiotics: Growth medium without antibiotics | Size: 500 ml | CAT.#: 415A-500 | Price: $128.00 | |
| HFLS Growth Medium wo FBS: Growth medium without FBS | Size: 500 ml | CAT.#: 415F-500 | Price: $128.00 | |
| HFLS Growth Medium Kit: Basal medium & growth supplement sold together packaged separately | Size: Yields 500 ml | CAT.#: 415K-500 | Price: $128.00 | |
| HFLS Growth Supplement: Added to Basal Medium to create Growth Medium | Size: 50 ml | CAT.#: 415-GS | Price: $74.00 | |
| HFLS Starvation Medium: Use when cells need to be starved overnight to 24 hrs before experiment | Size: 250 ml | CAT.#: 415S-250 | Price: $72.00 |
Related Products
| Product | Size | CAT.# | Price | Quantity |
|---|---|---|---|---|
| Freezing Medium: For general cryopreservation of most primary cells. Contains FBS & DMSO. | Size: 50 ml | CAT.#: 040-50 | Price: $54.00 | |
| Subculture Reagent Kit: 100 ml each of HBSS, Trypsin/EDTA & Trypsin Neutralizing Solution | Size: 1 Kit | CAT.#: 090K | Price: $63.00 |
Extended Family Products
| Product | Size | CAT.# | Price | Quantity |
|---|---|---|---|---|
| Cyto-X Cell Counting Reagent: 500 tests | Size: 1 Bottle | CAT.#: 028-01 | Price: $160.00 | |
| Cyto-X Cell Counting Reagent Sample: 100 tests | Size: Sample | CAT.#: 028-S | Price: $41.00 |
Resources/Documents
Publications
2017
Jones, D., A. Jenny, J. Swantek, J. Burke, D. Lauffenburger and P. Sorger. 2017. Profiling drugs for rheumatoid arthritis that inhibit synovial fibroblast activation. Nature Chem Biol, 13:38-45.
Yao, Y., C. Jiang, N. Sun, W. Li, Y. iu, H. Han, Z. Miao, X. Zhao, J. Zhao and J. Li. 2017. Tamaractam, a New Bioactive Lactam from Tamarix ramosissima, Induces Apoptosis in Rheumatoid Arthritis Fibroblast-Like Synoviocytes. Molecules 22:96.
2016
Gharay, A., Y. Li, R. Kilani, and R Hartwell. 2016. Anti-Fibrogenic Compounds, Methods and Uses Thereof. Patent Application US 20160120857 A1.
Jones, D., A. Jenny, J. Swantek, J. Burke, D. Lauffenburger and P. Sorger. 2016. Profiling drugs for rheumatoid arthritis that inhibit synovial fibroblast activation. Nature Chemical Biology, doi:10.1038/nchembio.2211.
Sable, R., T. Durek, V. Taneja, D. Craik, S. Pallerla, T. Gauthier and S. Jois. 2016. Constrained Cyclic Peptides as Immunomodulatory Inhibitors of the CD2:CD58 Protein-Protein interaction. ACS Chem Biol, 11:2366-2374.
Sable, R., T. Durek, V. Taneja, D. Craik, S. Pallerla, S. Pallerla, T. Gautheir and S. Jois. 2016. Constrained Cyclic Peptides as Immunomodulatory Inhibitors of the CD2:CD58 Protein–Protein Interaction. ACS Chem Biol, 11:2366–2374.
Shekhani, M., T. Forde, A. Adilbayeva, M. Ramez, A. Myngbay, Y. Bexeitov, V. Lindner and M. Ramez. 2016. Collagen triple helix repeat containing 1 is a new promigratory marker of arthritic pannus. Arthritis Research & Therapy, 18:171.
Tan, L., D. Gurbani, E. Weisberg, D. Jones, S. Rao, W. Singer, F. Bernard, S. Mowafy, A. Jenney, G. Du, A. Nonami, J. Griffin, D. Lauffenburger, K. Westover, P. Sorger and N. Gray. 2016. Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Bioorganic & Med Chem, dx.doi.org/10.1016/j.bmc.2016.11.034.
2015
Auer, J. M. Bader, J. Fischer, H. Kettenberger, M. Hilger, S. Lorenz, and J. Moelleken. 2015. BISPECIFIC ANTIBODIES AGAINST HUMAN TWEAK AND HUMAN 1L17 AND USES THEREOF. Patent Application US 20150132307 A1.
Padley, R. and R. Heuser. 2015. Compositions and Methods for Treating Rheumatoid Arthritis. Patent Application US20150291689A1.
Yoshioka, R.0, Y. Kita, A. Nagahira, A. Manno, N. Makita, U. Tomita, and M. Murakawa. 2015. Quantitative analysis of cadherin-11 and β-catenin signalling during proliferation of rheumatoid arthritis-derived synovial fibroblast cells. Journal of Pharmacy and Pharmacology, DOI: 10.1111/jphp.12410.
Zhang, W., Z. Du, J. Zhu, J. Yu and Y. Xu. 2015. Sprouty2 suppresses the inflammatory responses in rheumatoid arthritis fibroblast-like synoviocytes through regulating the Raf/ERK and PTEN/AKT signals. Molec Immunol, 67:532-539.
Zhang, W., J. Zhu, Z. Du, J. Yu, Y. Xu and F. Wang. 2015. Intraarticular gene transfer of SPRY2 suppresses adjuvant-induced arthritis in rats. Applied Microbiol & Biotech, 99:6727-6735.
2014
Braun, H., H. Kim,, C. Chu and J. Dragoo. 2014. The Effect of Platelet-Rich Plasma Formulations and Blood Products on Human Synoviocytes: Implications for Intra-articular Injury and Therapy. Am J Sports Med. 42:1204-1210.
Hashizume, M. and M. Mihara. 2014. Combination of High-Molecular-Weight Hyaluronic Acid and Cytokine Inhibitor Potently Inhibits Expression of Joint-Damage-Related Genes Induced By Synovial Fluid of RA Patients. J Arthritis, 3:1.
Yuan, H., P. Yang, D. Zhou, W. Gao, Z. Qiu, F. Fang, S. Ding and W. Xiao. 2014. Knockdown of sphingosine kinase 1 inhibits the migration and invasion of human rheumatoid arthritis fibroblast-like synoviocytes by down-regulating the PI3K/AKT activation and MMP-2/9 production in vitro. Mol Biol Rep, 41:5157-5165.
2012
Brys, R., N. Vangeghinste, P. Tomme, H. Johanus, and M. Klaassen. 2012. Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases. Patent US 8097408 B2
Evanko, S.P., S. Potter-Perigo, P.L. Bollyky, G.T. Nepom, and T.N. Wight. 2012. Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration. Matrix Biology. 31:90-100.
Hsu, J., Y. Gu, S.-L. Tan, S. Narula, J.A. DeMartino, and C. Liao. 2012. Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: A potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints. Immunology letters, 150:97-104.
Tsuji, F., K. Oh-hashi and K. Kiuchi. 2012. Differential effects of Akt pathway inhibitors on IL-1β-induced protein phosphorylation in human fibroblast-like Synoviocytes. J Receptors & Signal Transd, 32:22-28.
Yamaguchi, A., K. Nozawa, M. Fujishiro, M. Kawasaki, K. Takamori, H. Ogawa, I. Sekigawa, and Y. Takasaki. 2012b. Estrogen inhibits apoptosis and promotes CC motif chemokine ligand 13 expression on synovial fibroblasts in rheumatoid arthritis. Immunopharmacology and Immunotoxicology. 34:852-857.
2011
Brys, R., N. Vandeghinste, and P. Tomme. 2011. Methods for identification, and compounds useful for the treatment of degenerative and inflammatory diseases. Patent US 7919259 B2.
Chen, D.P., C.K. Wong, L.S. Tam, E.K. Li, and C.W. Lam. 2011. Activation of human fibroblast-like synoviocytes by uric acid crystals in rheumatoid arthritis. Cellular & molecular immunology. 8:469-478.
Chen, D.-P., C.-K. Wong, P.-C. Leung, K.-P. Fung, C.B.-S. Lau, C.-P. Lau, E.K.-M. Li, L.-S. Tam, and C.W.-K. Lam. 2011b. Anti-inflammatory activities of Chinese herbal medicine sinomenine and Liang Miao San on tumor necrosis factor-α-activated human fibroblast-like synoviocytes in rheumatoid arthritis. Journal of ethnopharmacology. 137:457-468.
2010
Brys, R., N. Vandeghinste, and P. Tomme. 2010. Methods for identification, and compounds useful for the treatment of degenerative and inflammatory diseases. Patent Application EP 2 256 197 A1.
El-Beialy, W., N. Galal, Y. Deyama, Y. Yoshimura, K. Suzuki, K. Tei, and Y. Totsuka. 2010. Effects of Estrogen on PMCA 2 and 4 in Human Fibroblast-like Synovial Cells and Mouse Macrophage-like Cells. Endocrine J, 57:93-97.
Freimanis, G., P. Hooley, H.D. Ejtehadi, H. Ali, A. Veitch, P. Rylance, A. Alawi, J. Axford, A. Nevill, and P.G. Murray. 2010. A role for human endogenous retrovirus‐K (HML‐2) in rheumatoid arthritis: investigating mechanisms of pathogenesis. Clinical & Experimental Immunology. 160:340-347.
Suzuki, M., M. Hashizume, H. Yoshida, and M. Mihara. 2010. Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule. Rheumatol Int. 30:309-315.
2009
Nakamachi, Y., S. Kawano, M. Takenokuchi, K. Nishimura, Y. Sakai, T. Chin, R. Saura, M. Kurosaka, and S. Kumagai. 2009. MicroRNA‐124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast‐like synoviocytes from patients with rheumatoid arthritis. Arthritis & Rheumatism. 60:1294-1304.
Brys, R,. N. Vandeghinste, P. Tomme, and H. Klaassen. 2009. Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases. Patent US 7485468 B2.
Laurent, A., M. Proulx, and J. Jaquith. 2009. Functionalized pyrrolidines and use thereof as iap inhibitors. Patent Application US 20110117081 A1.